Niho S, et al. - Experts sought to report the results of the final overall survival (OS) of a feasibility study of long-term single-agent therapy with S-1 following docetaxel plus cisplatin therapy in patients with completely resected stage II or stage IIIA non–small cell lung cancer (TORG0809 study). In addition to being hopeful, the survival data obtained from this study are similar to those reported from a previous study conducted in Japan. In patients with stage II and stage IIIA non–small cell lung cancer, the 5-year OS rates were 76% and 68%, respectively. They noted 3.4 years to be the median recurrence-free survival (RFS) duration. A total of 68 patients demonstrated disease recurrence, and second-line chemotherapy was received by 62 of these patients. The brain and mediastinal lymph nodes were the most common sites of recurrence.